Recent Findings from Amsterdam University Medical Center Highlight Research in Anemia (A National Programme of a High Throughput Axiom Array Genotyping Platform for HEA and HLA Testing for All Patients with Sickle Cell, Thalassaemia and...).

A recent report from Amsterdam University Medical Center highlights the implementation of a national program in the United Kingdom for high-throughput genotyping of Human Erythroid Antigen (HEA) and Human Leukocyte Antigen (HLA) types for patients with sickle cell, thalassemia, and rare inherited anemias. The program aims to improve blood matching for patients and donors, potentially enabling curative treatments for certain conditions. The study involved collaboration with various stakeholders and patient advocacy groups, with over 3,500 DNA samples from diverse genetic ancestry groups tested. The research emphasizes the need for continued advancements in blood typing technology and implementation at a population scale. [Extracted from the article]